# Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

> **NCT00857415** · PHASE3 · COMPLETED · sponsor: **Avid Radiopharmaceuticals** · enrollment: 226 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** florbetapir F 18

## Key facts

- **NCT ID:** NCT00857415
- **Lead sponsor:** Avid Radiopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-03
- **Final completion:** 2010-05
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2012-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857415, "Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00857415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*